Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported $243.8 million in fourth-quarter 2025 revenue and $868.5 million in full-year net product revenue from its narcolepsy drug WAKIX, …
Harmony Biosciences Reports 2025 Revenue Growth, Issues 2026 Outlook Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) said the U.S. Food and Drug Administration has approved a supplemental new drug application for WAKIX (pitolisant) tablets to treat cataplexy in …
FDA Approves Harmony’s WAKIX for Pediatric Cataplexy Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) said it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before U.S. …
Harmony Biosciences to Report Q4 and Full-Year 2025 Results Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) said preliminary, unaudited net product revenue for its lead narcolepsy drug WAKIX reached approximately $868 million in 2025, setting the …
Harmony’s WAKIX Surges Toward Blockbuster Status as Revenue Nears $1 Billion Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported new late-stage clinical data showing its experimental epilepsy drug EPX-100 delivered sharp and sustained seizure reductions in patients with …
Harmony’s Epilepsy Drug Cuts Seizures in Half in Key Late-Stage Study Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently reported encouraging data from its pivotal bioequivalence study for pitolisant gastro-resistant (GR), marking a major milestone as the company …
Harmony’s Next-Gen Narcolepsy Drug Advances With Surprising New Results Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has begun dosing participants in a Phase 1 clinical study of BP1.15205, a next-generation orexin 2 receptor agonist positioned as …
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will showcase its strategy and pipeline to the investment community next week, with executives slated to appear at three major …
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences Read More PLYMOUTH MEETING, PA — Harmony Biosciences posted another quarter of rapid expansion, driven by accelerating demand for its flagship narcolepsy therapy WAKIX® and a late-stage pipeline approaching multiple Phase 3 …
Harmony Biosciences Surges on Strong WAKIX Growth as Cash Position Climbs to $778M Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported topline results from its Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome (FXS), announcing that the trial …
Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights Read More